Engaging Mother-Infant Dyads in Hepatitis C Care through Perinatal Pediatric Infectious Diseases Consultation

Epstein RL, Moloney C, Pelton SI Department of Pediatrics, Section of Infectious Diseases, Boston Medical Center, Boston University School of Medicine September 13, 2019





Disclosures



EXCEPTIONAL CARE. WITHOUT EXCEPTION.

• No relevant disclosures



EXCEPTIONAL CARE. WITHOUT EXCEPTION

- Opioid use disorder (OUD) prevalence among pregnant women in the United States quadrupled from 1999-2014¹
- 50-84% of pregnant women with OUD are HCV seropositive²⁻⁵




1. Haight MMWR 2018 2. Liu Med J Aust 2009, Krans Subst Abuse 2016, Page Mat Child Health 2017, Epstein J Peds 2018



EXCEPTIONAL CARE. WITHOUT EXCEPTION

- Opioid use disorder (OUD) prevalence among pregnant women in the United States quadrupled from 1999-2014¹
- 50-84% of pregnant women with OUD are HCV seropositive²⁻⁵



1. Haight MMWR 2018 2. Liu Med J Aust 2009, Krans Subst Abuse 2016, Page Mat Child Health 2017, Epstein J Peds 2018



EXCEPTIONAL CARE. WITHOUT EXCEPTION

Boston Medical Center: ~75 HCV seropositive women deliver each year, 95% with documented opioid use

Recovery Empowerment Social Services Prenatal Care Education Community Treatment



CATALYST OBAT

SOFAR

(Supporting Our Families through Addiction and Recovery) Pediatric Infectious Diseases



EXCEPTIONAL CARE. WITHOUT EXCEPTION

- Boston Medical Center: ~75 HCV seropositive women deliver each year, 95% with documented opioid use
- Study Aim: To evaluate whether a maternal-child linkage consult through pediatric infectious diseases improves maternal HCV treatment rates

Recovery Empowerment Social Services Prenatal Care Education Community Treatment



CATALYST OBAT

SOFAR

(Supporting Our Families through Addiction and Recovery) Pediatric Infectious Diseases

PROGRAM / INTERVENTION:

- Maternal-Child Health Coordinator Consult initiated in 10/2016 for all pregnant women identified as HCV seropositive
- Visit during delivery hospitalization, appointment coordination, contact during outpatient visits at BMC




PROGRAM / INTERVENTION:

- Maternal-Child Health Coordinator Consult initiated in 10/2016 for all pregnant women identified as HCV seropositive
- Visit during delivery hospitalization, appointment coordination, contact during outpatient visits at BMC

ANALYSIS:


- Retrospectively evaluated HCV+ women delivering at BMC 1/2014 - 5/2018
- Primary Outcome: Linkage to HCV treatment (by medication prescribed), time to Rx

HCV Care Cascade



*Percentages all conditional on the prior cascade step, except Linked to Care (/Viremic)

Mean Days to HCV Treatment Prescription from Delivery Date, by quarter of delivery



Conclusions/implications

• HCV Treatment increased over the study period (2014-2018), with 33% of women in the post-intervention period treated (OR 1.98, CI 1.08-3.65) - despite less follow-up time



Conclusions/implications

- HCV Treatment increased over the study period (2014-2018), with 33% of women in the post-intervention period treated (OR 1.98, CI 1.08-3.65) - despite less follow-up time
- Over half 57% were treated in primary care by internists trained in HCV care



Conclusions/implications

- HCV Treatment increased over the study period (2014-2018), with 33% of women in the post-intervention period treated (OR 1.98, CI 1.08-3.65) - despite less follow-up time
- Over half 57% were treated in primary care by internists trained in HCV care
- Perinatal care may represent a unique opportunity to link women and infants to HCV cure

Acknowledgements





- We would like to thank all patients, staff, and faculty in the Boston Medical Center RESPECT, SOFAR, GIM, Adult and Pediatric Infectious Diseases, and CATALYST clinics for making this study possible; and in particular, Carole Moloney for all of her great work getting mothers, infants (and fathers) into care!
- Jake Garfinkel, Elisha Wachman, and Davida Schiff